Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer
Estrid Høgdall(University of Copenhagen), Torben Steiniche(Aarhus University), Sarah M. Sørensen(University of Copenhagen), Claus Høgdall(Copenhagen University Hospital), Stephen J. O’Keefe(University of Pittsburgh), Thao Vo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lingkang Huang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lotte Nedergaard(University of Copenhagen), Matthew J. Marton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Busch-Sørensen(Center for Clinical & Basic Research), Else Mejlgaard, Wei Zhou(Broad Institute), Jeanette Bæhr Georgsen(Aarhus University Hospital)
Cited by 9
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
|The Lancet Oncology|2013|434
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
|Nature Communications|2021|386